Firefly Neuroscience, Inc. reported significant financial developments in its latest 10-Q filing for the third quarter of 2025, showcasing a notable increase in revenue and a strategic acquisition aimed at enhancing its product offerings. The company generated revenue of $388,000 for the three months ended September 30, 2025, compared to just $33,000 in the same period of the previous year, marking a 1,076% increase. For the nine months ended September 30, 2025, revenue reached $730,000, up from $55,000 in the prior year, reflecting a 1,227% increase. This surge in revenue is primarily attributed to the acquisition of Evoke Neuroscience, which contributed to the company's product sales.
Despite the increase in revenue, Firefly Neuroscience reported a net loss of $2.6 million for the third quarter, a decrease from a loss of $4.3 million in the same quarter of 2024. For the nine-month period, the net loss was $17.4 million, compared to $6.7 million in the previous year. The company’s operating expenses totaled $6.8 million for the nine months ended September 30, 2025, slightly higher than the $6.7 million reported for the same period in 2024. The increase in operating expenses was driven by general and administrative costs, which rose due to additional expenses related to directors and officers insurance following the merger.
In terms of strategic developments, Firefly completed the acquisition of Evoke Neuroscience on April 30, 2025, for a total consideration of approximately $6 million, which included $3 million in cash and shares of common stock. This acquisition is expected to enhance Firefly's capabilities in measuring brain activity and expand its customer base. The company has also been actively engaging in financing activities, raising $11.4 million through various offerings and warrant exercises during the nine months ended September 30, 2025, compared to $4.4 million in the same period of 2024.
Operationally, Firefly has made strides in expanding its product offerings and customer engagement. The company reported an increase in cash reserves, ending the quarter with $4.3 million in cash, up from $1.8 million at the end of 2024. The total assets of the company increased to $12.4 million as of September 30, 2025, compared to $4.6 million at the end of the previous fiscal year. However, the company continues to face challenges, including an accumulated deficit of $108.9 million and ongoing negative cash flows from operations, raising concerns about its ability to continue as a going concern.
Looking ahead, Firefly Neuroscience aims to leverage its recent acquisition and enhance its product commercialization efforts. The company plans to focus on expanding its sales organization and increasing market penetration for its EEG technology. Management has expressed confidence in its ability to raise additional capital to support ongoing operations and product development, although it acknowledges the uncertainties surrounding market conditions and the need for continued investment in its business strategy.
About FIREFLY NEUROSCIENCE, INC.
Firefly Neuroscience develops AI-driven neurophysiological assessment tools, notably the FDA-cleared BNA Platform, which analyzes EEG data to aid in diagnosing and managing neurological and mental health disorders. Its solutions support personalized treatment, clinical research, and drug development, targeting healthcare providers and pharmaceutical companies. Leveraging extensive proprietary databases and advanced machine learning, the company aims to transform brain health diagnostics and improve patient outcomes.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.